Skip to Content

Bravelle (urofollitropin) Disease Interactions

There are 6 disease interactions with Bravelle (urofollitropin):

Major

Follicle stimulating hormone (applies to Bravelle) adrenal dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Adrenal Insufficiency, Hyperadrenocorticism

The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled adrenal dysfunction. Uncontrolled adrenal dysfunction may involve the pituitary gland and be associated with a tumor or other dysfunction. Administration of FSH may exacerbate the condition.

References

  1. "Product Information. Gonal-F (follicle stimulating hormone)." Serono Laboratories Inc, Norwell, MA.
  2. "Product Information. Follistim (follicle stimulating hormone)." Organon, West Orange, NJ.
Major

Follicle stimulating hormone (applies to Bravelle) thyroid dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Hyperthyroidism, Hypothyroidism

The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled thyroid dysfunction. FSH is composed of both an alpha and beta subunit. The amino acid sequence of the alpha subunit of FSH is identical to that of TSH. Therefore, FSH may have weak TSH receptor- binding and activation.

References

  1. "Product Information. Gonal-F (follicle stimulating hormone)." Serono Laboratories Inc, Norwell, MA.
  2. "Product Information. Follistim (follicle stimulating hormone)." Organon, West Orange, NJ.
Major

Follicle stimulating hormone (applies to Bravelle) tumors

Major Potential Hazard, High plausibility. Applicable conditions: Neoplasia -- Estrogen Dependent

The use of follicle stimulating hormone is contraindicated in patients with sex hormone-dependent tumors of the reproductive tract and accessory organs (ovary, breast, uterus) and in patients with pituitary tumors. FSH is required for normal sex hormone production, which may be detrimental in these patients. Patients in later reproductive life have a greater predisposition to endometrial carcinoma.

References

  1. "Product Information. Gonal-F (follicle stimulating hormone)." Serono Laboratories Inc, Norwell, MA.
  2. "Product Information. Follistim (follicle stimulating hormone)." Organon, West Orange, NJ.
Major

Gonadotropins (applies to Bravelle) thromboembolism

Major Potential Hazard, Moderate plausibility. Applicable conditions: Thrombotic/Thromboembolic Disorder, History - Thrombotic/Thromboembolic Disorder, Obesity

Thromboembolic events, including venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebrovascular occlusion (stroke), and arterial occlusion resulting in loss of limb, have been reported during administration of gonadotropin therapy, both in association with and independent of the Ovarian Hyperstimulation Syndrome. Therapy with gonadotropins should be administered cautiously to patients with or predisposed to thromboembolism.

References

  1. "Product Information. Humegon (menotropins)." Organon, West Orange, NJ.
Major

Urofollitropin (applies to Bravelle) intracranial tumors

Major Potential Hazard, Moderate plausibility. Applicable conditions: Brain/Intracranial Tumor, Pituitary Tumor

The use of urofollitropin is contraindicated in the presence of any intracranial lesion or tumor.

Moderate

Gonadotropins (applies to Bravelle) pulmonary conditions

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment

Serious pulmonary conditions such as atelectasis, acute respiratory syndrome, and exacerbation of asthma have been reported in women treated with gonadotropins. Caution and monitoring is advised if used in women with pulmonary conditions.

Bravelle (urofollitropin) drug interactions

There is 1 drug interaction with Bravelle (urofollitropin)

Bravelle (urofollitropin) alcohol/food interactions

There is 1 alcohol/food interaction with Bravelle (urofollitropin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.